• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Important modifications in pharmacovigilance of the EAEU in 2017

10.08.2021/in Publications /by Marketing

2017 was an important date in the history of pharmacovigilance in Russia and the countries of the Eurasian Economic Union (EAEU). The legal framework for pharmacovigilance activities was completely updated and unified rules for pharmacovigilance were introduced for all EAEU member countries in accordance with the requirements of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union (Decision №87 of 03.11.2016).

 The agreements of the EAEU countries on the general principles of drug circulation indicate that national pharmacovigilance systems are brought into compliance with the Good Pharmacovigilance Practices, and there is no transition period.

 At the moment the legislations of the EAEU member countries are harmonized with the requirements of the Good Practice. For example, in Russia in February 2017 Order No. 1071 “On Approval of the Procedure for Pharmacovigilance” was approved, and in Armenia Order No. N23-N of May 17, 2017. “On approval of the procedure for registration, collection, reporting and reporting, monitoring and analysis of data on suspected adverse reactions, lack of therapeutic effectiveness, misuse and suspected falsification of medicines, as well as the registration log form and the report card on suspected adverse reactions, lack of therapeutic effectiveness, misuse and suspected falsification of medicines”.

In the near future it is also planned to introduce rules governing the inspection of pharmacovigilance systems of holders of drug registration certificates.

Already now such requirements are mandatory as:

  • Designation of a Pharmacovigilance Authorized Person in each Company;
  • Development and maintenance of the Pharmacovigilance System Master File;
  • Development and implementation of standard operating procedures describing all drug safety management processes;
  • Having a validated database to store drug safety information;
  • Collection, registration and timely reporting of information on cases of adverse reactions during the use of medicines;
  • Development and timely submission of periodic safety reports on both registered and investigational drugs;
  • Conducting regular audits of the pharmacovigilance system;
  • Arranging for proper storage and archiving of pharmacovigilance documentation.

Good pharmacovigilance practices and local legislative acts of EAEU member states regulate strict requirements for the Authorized person on pharmacovigilance, his education, and qualification, as well as a significant number of requirements to the organization of storage of data related to pharmacovigilance (presence of “audit trail”, protection of access to confidential patient data, etc.), strict terms of safety information, ongoing risk-benefitq assessment of all medicines and periodic audits of their system Because of this, an increasing number of pharmaceutical companies, are turning to firms that provide professional pharmacovigilance services. This allows both budget savings and highly qualified services without the time and effort required to recruit staff, train them constantly, and constantly monitor the new regulatory requirements adopted by different countries.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 1 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Ensuring continuity of Pharmacovigilance activities in a COVID pandemic CENTRALIZED DATA MONITORING IN CLINICAL TRIALS
Scroll to top